Giorgio Ottaviani,
Operating Partner, Head of Non-Clinical Development

Giorgio joined Ridgeline/Versant in 2018 from Roche where he served as Global Head of Pharmacokinetics and as Site Head of Non-Clinical Safety in Shanghai. Prior to Roche Giorgio worked at Novartis, Merck-Serono, and in the biotech industry.

Giorgio brings broad development expertise across therapeutic areas and modalities and proven abilities to build and lead new companies. Giorgio’s contributions in newcos formation include Black Diamond Therapeutics, Monte Rosa Therapeutics, Bright Peak Therapeutics, Vertical Bio and Granite Bio.

Giorgio earned a Ph.D. in Pharmaceutical Chemistry from the University of Geneva (Switzerland) and is a certified toxicologist from the American Board of Toxicology (DABT).